These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 37767607)

  • 1. National and regional differences in meningococcal vaccine recommendations for individuals at an increased risk of meningococcal disease.
    Burman C; Findlow J; Marshall HS; Safadi MAP
    Expert Rev Vaccines; 2023; 22(1):839-848. PubMed ID: 37767607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeling the public health impact of different meningococcal vaccination strategies with 4CMenB and MenACWY versus the current toddler MenACWY National Immunization Program in Chile.
    Graña MG; Cavada G; Vasquez M; Shen J; Maervoet J; Klint J; Gómez JA
    Hum Vaccin Immunother; 2021 Dec; 17(12):5603-5613. PubMed ID: 34890520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolving strategies for meningococcal vaccination in Europe: Overview and key determinants for current and future considerations.
    Martinón-Torres F; Taha MK; Knuf M; Abbing-Karahagopian V; Pellegrini M; Bekkat-Berkani R; Abitbol V
    Pathog Glob Health; 2022 Mar; 116(2):85-98. PubMed ID: 34569453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020.
    Mbaeyi SA; Bozio CH; Duffy J; Rubin LG; Hariri S; Stephens DS; MacNeil JR
    MMWR Recomm Rep; 2020 Sep; 69(9):1-41. PubMed ID: 33417592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Cohn AC; MacNeil JR; Clark TA; Ortega-Sanchez IR; Briere EZ; Meissner HC; Baker CJ; Messonnier NE;
    MMWR Recomm Rep; 2013 Mar; 62(RR-2):1-28. PubMed ID: 23515099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential public health impact of a
    Huang L; Snedecor SJ; Balmer P; Srivastava A
    Postgrad Med; 2022 May; 134(4):341-348. PubMed ID: 33615973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meningococcal Vaccination of Adolescents in the United States: Past Successes and Future Considerations.
    Presa J; Findlow J; Zimet GD
    J Adolesc Health; 2024 Jun; 74(6):1068-1077. PubMed ID: 38430074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of Meningococcal Vaccines at Reducing Invasive Meningococcal Disease and Pharyngeal Neisseria meningitidis Carriage: A Systematic Review and Meta-analysis.
    McMillan M; Chandrakumar A; Wang HLR; Clarke M; Sullivan TR; Andrews RM; Ramsay M; Marshall HS
    Clin Infect Dis; 2021 Aug; 73(3):e609-e619. PubMed ID: 33212510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changing patterns of invasive meningococcal disease and future immunization strategies.
    Taha MK; Bekkat-Berkani R; Abitbol V
    Hum Vaccin Immunother; 2023 Dec; 19(1):2186111. PubMed ID: 37017273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Need for Optimisation of Immunisation Strategies Targeting Invasive Meningococcal Disease in the Netherlands.
    Bousema JC; Ruitenberg J
    Int J Health Policy Manag; 2015 Sep; 4(11):757-61. PubMed ID: 26673336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review of the immunogenicity, safety and current recommendations for the meningococcal serogroup B vaccine, MenB-FHbp.
    Burman C; Alderfer J; Snow VT
    J Clin Pharm Ther; 2020 Apr; 45(2):270-281. PubMed ID: 31820483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and safety of MenACWY-TT, a quadrivalent meningococcal tetanus toxoid conjugate vaccine recently licensed in the United States for individuals ≥2 years of age.
    Marshall GS; Pelton SI; Robertson CA; Oster P
    Hum Vaccin Immunother; 2022 Nov; 18(6):2099142. PubMed ID: 35947774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modelling the impact of 4CMenB and MenACWY meningococcal combined vaccination strategies including potential 4CMenB cross-protection: An application to England.
    Beck E; Klint J; Garcia S; Abbing V; Abitbol V; Akerborg O; Argante L; Bekkat-Berkani R; Hogea C; Neine M; Vadivelu K; Whelan J; Meszaros K
    Vaccine; 2020 Nov; 38(47):7558-7568. PubMed ID: 32807531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An update of clinical experience with the quadrivalent meningococcal ACWY-CRM conjugate vaccine.
    Keshavan P; Pellegrini M; Vadivelu-Pechai K; Nissen M
    Expert Rev Vaccines; 2018 Oct; 17(10):865-880. PubMed ID: 30198805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 'Be on the TEAM' Study (Teenagers Against Meningitis): protocol for a controlled clinical trial evaluating the impact of 4CMenB or MenB-fHbp vaccination on the pharyngeal carriage of meningococci in adolescents.
    Carr J; Plested E; Aley P; Camara S; Davis K; MacLennan JM; Gray S; Faust SN; Borrow R; Christensen H; Trotter C; Maiden MCJ; Finn A; Snape MD;
    BMJ Open; 2020 Oct; 10(10):e037358. PubMed ID: 33093030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adolescent meningococcal serogroup A, W and Y immune responses following immunization with quadrivalent meningococcal A, C, W and Y conjugate vaccine: Optimal age for vaccination.
    van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Sanders EAM; Berbers GAM
    Vaccine; 2017 Aug; 35(36):4753-4760. PubMed ID: 28647167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel vaccine to prevent meningococcal disease beyond the first year of life: an early review of MenACYW-TT.
    Martinón-Torres F; Bertrand-Gerentes I; Oster P
    Expert Rev Vaccines; 2021 Sep; 20(9):1123-1146. PubMed ID: 34365870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First statewide meningococcal B vaccine program in infants, children and adolescents: evidence for implementation in South Australia.
    Marshall HS; Lally N; Flood L; Phillips P
    Med J Aust; 2020 Feb; 212(2):89-93. PubMed ID: 31909501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of regional disparities on the availability of meningococcal vaccines in the US.
    Schley K; Jodar E; Presa JV; Willis SJ; Prener CG
    BMC Public Health; 2024 Jul; 24(1):1771. PubMed ID: 38961431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disparities in healthcare providers' interpretations and implementations of ACIP's meningococcal vaccine recommendations.
    Huang L; Goren A; Lee LK; Li VW; Dempsey A; Srivastava A
    Hum Vaccin Immunother; 2020 Apr; 16(4):933-944. PubMed ID: 31634035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.